A Case of Central Serous Chorioretinopathy after Tadalafil Treatment
10.3341/jkos.2018.59.1.93
- Author:
Yo Sep YOON
1
;
Seunghwan LEE
;
Je Moon WOO
;
Jung Kee MIN
Author Information
1. Department of Ophthalmology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. mk2ace@daum.net
- Publication Type:Case Report
- Keywords:
Central serous chorioretinopathy;
Cialis®;
Phosphodiesterase (PDE)-5 inhibitor;
Tadalafil
- MeSH:
Blood Vessels;
Central Serous Chorioretinopathy;
Choroid;
Diagnosis;
Erectile Dysfunction;
Follow-Up Studies;
Humans;
Male;
Middle Aged;
Retina;
Retinal Pigment Epithelium;
Subretinal Fluid;
Tadalafil;
Vasodilator Agents;
Vision Disorders;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2018;59(1):93-97
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To describe a patient who presented with central serous chorioretinopathy after 2 months of tadalafil administration without any other underlying disease or medication. CASE SUMMARY: A 49-year-old male patient was transferred from a local clinic with metamorphopsia and decreased visual acuity in the right eye. His visual acuity was 6/20 in the right eye and 18/20 in the left eye. The fundus examination showed a large serous detachment between the superior and inferior blood vessel arcades in the right retina. In his medical history, he used tadalafil three times a week for 2 months. His medication was then stopped, and a follow-up examination was scheduled. After 2 months, a fundus examination showed resolution of the subretinal fluid, and his corrected visual acuity recovered to 20/20. CONCLUSIONS: Tadalafil (Cialis®) is a phosphodiesterase (PDE)-5 inhibitor and predominantly prescribed for the treatment of erectile dysfunction. PDE–5 inhibitors may be potent vasodilators in the retina and choroid, and may induce choroidal vessel engorgement leading to leakage across the retinal pigment epithelium and accumulation of subretinal fluid in selected patients. When making a diagnosis as central serous chorioretinopathy, the physician should confirm the causative drugs that are easy to miss, by performing a thorough review of the patient's medical history and promptly terminating the causative drugs.
